Hydroxychloroquine in the Treatment of COVID-19

Journal of Journal of Pharmaceutical Sciences & Emerging Drugs is announcing its special issue entitled “Hydroxychloroquine in the Treatment of COVID-19. It aims to spread the scientific information on the C0VID-19 and help the scientific world and researcher for the remedy and upgrading the research.

Special issue in this pandemic situation is to increase the quality of the journal, also to enhance the recent developments to prevent Covid 19.

Hydroxychloroquine and chloroquine are oral prescription drugs that have been used for treatment of malaria and certain inflammatory conditions. Hydroxychloroquine and chloroquine are under investigation in clinical trials for pre-exposure or post-exposure prophylaxis of SARS-CoV-2 infection, and treatment of patients with mild, moderate, and severe COVID-19. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of hydroxychloroquine sulfate supplied from the Strategic National Stockpile to treat adults and adolescents who weigh 50 kg or more and are hospitalized with COVID-19 for whom a clinical trial is not available, or participation is not feasible. This EUA is for the unapproved use of hydroxychloroquine sulfate supplied from the Strategic National Stockpile (SNS) to treat adults and adolescents who weigh 50 kg or more and are hospitalized with COVID-19 for whom a clinical trial is not available, or participation is not feasible.

The special issue follows the below scope but not limited to:

• Hydroxychloroquine on the treatment
• New emerging Drugs
• Plasma Therapy
• Treatment of COVID-19
• Pharmaceutical Research